Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 5/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | VEGFA | P15692 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | EPAS1 | Q99814 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25587196 | 0.84 | ALDH1A1 (0.41) | PPARGGAAVEGFAKDM4E | |
| SCHEMBL2034696 | 0.84 | PPARG (0.50) | PPARGGAAHTTVEGFAEPAS1 | |
| SCHEMBL2029760 | 0.84 | PPARG (0.52) | PPARGGAAHTTKDM4E | |
| SCHEMBL24570024 | 0.82 | VEGFA (0.41) | PPARGVEGFAEPAS1CYP1A2CYP3A4 | |
| SCHEMBL2032911 | 0.82 | PPARG (0.51) | PPARGVEGFAEPAS1 | |
| SCHEMBL2033066 | 0.82 | VEGFA (0.43) | PPARGGAAHTTVEGFAEPAS1 | |
| SCHEMBL29888021 | 0.82 | VEGFA (0.41) | PPARGVEGFAEPAS1CYP1A2CYP3A4 | |
| SCHEMBL5570133 | 0.81 | ALDH1A1 (0.41) | PPARGKDM4ECYP3A4 | |
| SCHEMBL30354830 | 0.81 | ALDH1A1 (0.41) | PPARGKDM4ECYP3A4 | |
| SCHEMBL13928134 | 0.81 | PPARG (0.53) | PPARGGAAHTTVEGFAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1053227-B1 | PPAR-GAMMA MODULATORS | AMGEN INC (US) | 2008-11-05 | — | — | EP | disclosed |
| US-7439242-B2 | PPARγ modulators | AMGEN INC. (US) | 2008-10-21 | — | — | US | disclosed |
| US-6620827-B2 | Peroxisome proliferator-activated receptors-gamma to control lipid metabolism ane obesity; antidiabetic, -inflammatory and -arthritic agents; non-insulin dependent diabetes; antilipemic and -cholesterol agents | TULARIK INC. | 2003-09-16 | — | — | US | disclosed |
| US-20030088103-A1 | PPARgamma modulators | TULARIK INC. (US) | 2003-05-08 | — | — | US | disclosed |
| US-20010027200-A1 | PPARgamma modulators | TULARIK INC. | 2001-10-04 | — | — | US | disclosed |
| US-6200995-B1 | PYRIDYLOXYBENZENESULFONAMIDE DERIVATIVES; DIABETES, OBESITY | TULARIK INC. | 2001-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030088103-A1 | PPARgamma modulators | PPARG, PPARA, PPARD | PPARG 1/4885GAA 782/4885HTT 3507/4885 |
| US-20010027200-A1 | PPARgamma modulators | PPARG, PPARA, PPARD | PPARG 1/4885GAA 782/4885HTT 3507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.